Tenet Healthcare
THC
$280.77
+3.00%
Tenet Healthcare is a diversified healthcare services company headquartered in Dallas, operating acute and specialty hospitals, ambulatory surgery centers, and outpatient facilities across the southern United States, along with its Conifer revenue cycle management segment. As one of the largest for-profit hospital operators in the U.S., Tenet differentiates itself through an integrated care model that combines hospital operations with ambulatory services and technology-enabled revenue cycle solutions. The current investor narrative centers on the company's robust earnings growth and margin expansion, driven by operational efficiencies and strategic portfolio optimization, despite recent revenue softness attributed to an unfavorable patient admissions mix. With a strong buy consensus and a recent surge in share price, the market is debating whether Tenet's operational momentum can sustain its valuation re-rating amid ongoing industry headwinds.…
THC
Tenet Healthcare
$280.77
Investment Opinion: Should I buy THC Today?
Based on the analysis, THC is rated a Buy. The company's strong earnings growth, margin expansion, and low valuation relative to peers provide a compelling investment case. The consensus rating is Strong Buy, and the average analyst target of $282.48 suggests modest upside, but the high target of $309 implies 10.1% potential. The thesis is that THC's operational efficiencies and strategic focus on high-margin services will continue to drive earnings growth, justifying a re-rating of the stock.
Sign up to view all
THC 12-Month Price Forecast
The AI assessment is bullish on THC, driven by its strong earnings growth and attractive valuation. The company's ability to expand margins despite revenue headwinds is a positive signal, and the low PE suggests the market is not fully appreciating its earnings power. However, the limited upside to analyst targets and high debt levels temper confidence. The stance would be upgraded to high confidence if revenue growth accelerates above 4% and the stock breaks above $290. Conversely, a downgrade to neutral would occur if margins compress below 10% or the stock falls below $250.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tenet Healthcare's 12-month outlook, with a consensus price target around $282.48 and implied upside of +0.6% versus the current price.
Average Target
$282.48
0 analysts
Implied Upside
+0.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$260 - $309
Analyst target range
Tenet Healthcare is covered by 21 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.5). The average price target is $282.48, implying a modest 0.6% upside from the current price of $280.77. The distribution of ratings is heavily skewed toward buy, with 10 recent actions from firms like Wells Fargo, Barclays, and RBC Capital all maintaining Overweight or Buy ratings. The target price range spans from a low of $260.00 to a high of $309.00, with the high target suggesting a 10.1% upside, while the low target implies a 7.4% downside. The relatively narrow spread between the low and high targets (about 19%) indicates a moderate level of conviction among analysts, though the consensus is clearly bullish. The high target likely assumes continued margin expansion and successful execution of the company's growth strategy, while the low target may reflect concerns about regulatory changes or a slowdown in patient volumes.
Drowning in data?
Find the real signal!
Bulls vs Bears: THC Investment Factors
Tenet Healthcare presents a compelling bull case driven by robust earnings growth, margin expansion, and a low valuation relative to peers. The company's net margin nearly doubled year-over-year, and its PE of 12.73x is well below the industry average, suggesting the market is undervaluing its earnings power. However, bearish concerns include high debt levels, decelerating revenue growth, and limited upside to analyst targets after a sharp price surge. The most critical tension is whether the company can sustain its margin expansion and earnings growth despite revenue headwinds. If margins hold and revenue reaccelerates, the stock could re-rate higher; if not, the current valuation may be justified, and the stock could consolidate. Overall, the bull case currently has stronger evidence, given the strong earnings beat and raised guidance, but the limited upside to targets warrants caution.
Bullish
- Strong earnings growth and margin expansion: Q1 2026 net income surged to $702M from $406M a year ago, with net margin expanding from 7.77% to 13.08%. Operating margin improved to 16.43% despite a revenue mix shift, demonstrating operational leverage and cost discipline.
- Attractive valuation with low PE: Trailing PE of 12.73x and forward PE of 13.47x are well below the industry average of 22x, implying a 42% discount. This suggests the market is not fully pricing in the company's earnings power, offering potential upside if growth persists.
- Strong analyst consensus and price targets: 21 analysts rate THC a Strong Buy (mean 1.5), with an average target of $282.48, only 0.6% above the current price. The high target of $309 implies 10.1% upside, reflecting confidence in continued execution.
- Robust free cash flow generation: TTM free cash flow stands at $3.349B, providing ample liquidity for debt reduction, share buybacks, or strategic investments. This supports the company's ability to manage its high debt load and fund growth initiatives.
Bearish
- High debt levels increase financial risk: Debt-to-equity ratio of 3.12 is elevated, and interest expense of $205M per quarter consumes a significant portion of operating income. While cash flow is strong, a downturn could strain debt servicing capabilities.
- Revenue growth decelerating: Q1 2026 revenue grew only 2.78% YoY, down from 4.5% in Q1 2025, and sequentially declined from $5.527B to $5.368B. The company cited an unfavorable admissions mix, which could persist and limit top-line expansion.
- Limited upside to analyst targets: The average analyst target of $282.48 is just 0.6% above the current price of $280.77, indicating that the stock has already priced in much of the expected upside. The low target of $260 implies a 7.4% downside.
- High beta and market volatility: With a beta of 1.23, THC is 23% more volatile than the market. In a market downturn, the stock could decline more than the S&P 500, as evidenced by its max drawdown of -34.08% over the past year.
THC Technical Analysis
Tenet Healthcare's stock is in a powerful uptrend, with a 1-year price change of +58.28% and a 6-month change of +22.13%. The current price of $280.77 sits just 0.04% below its 52-week high of $280.89, effectively at the top of its 52-week range (99.9% of the range). This positioning near the highs indicates strong momentum and investor confidence, though it also raises the risk of short-term overextension. The stock's beta of 1.23 implies it is 23% more volatile than the broader market, which is typical for a healthcare services name with operational leverage.
Beta
1.23
1.23x market volatility
Max Drawdown
-34.1%
Largest decline past year
52-Week Range
$158-$281
Price range past year
Annual Return
+58.3%
Cumulative gain past year
| Period | THC Return | S&P 500 |
|---|---|---|
| 1m | +43.7% | +3.6% |
| 3m | +61.6% | +2.7% |
| 6m | +22.1% | +11.4% |
| 1y | +58.3% | +18.7% |
| ytd | +40.8% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
THC Fundamental Analysis
Tenet's revenue trajectory shows modest growth, with Q1 2026 revenue of $5.368 billion, up 2.78% year-over-year, but slightly below the prior quarter's $5.527 billion. The revenue growth rate has decelerated from the 4.5% YoY growth seen in Q1 2025, reflecting a challenging admissions mix. However, the company's profitability is robust, with Q1 2026 net income of $702 million and a net margin of 13.08%, up from 7.77% in the year-ago quarter. Gross margin for Q1 2026 was 16.43%, which is lower than the 82.6% reported in Q1 2025 due to a change in cost classification, but operating margin improved to 16.43% from 17.25% in the prior year. The company's balance sheet shows a debt-to-equity ratio of 3.12, which is high but manageable given its strong cash flow generation, with free cash flow of $3.349 billion over the trailing twelve months and a current ratio of 1.76.
Quarterly Revenue
$5.4B
2026-03
Revenue YoY Growth
+2.8%
YoY Comparison
Gross Margin
16.4%
Latest Quarter
Free Cash Flow
$3.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is THC Overvalued?
Given Tenet's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 12.73x, while the forward PE is 13.47x, indicating that the market expects earnings to grow modestly in the next year. This is a low multiple for a company with strong profitability and growth prospects, suggesting the stock may be undervalued relative to its earnings power. Compared to the industry average PE of 22x (based on typical healthcare facilities), Tenet trades at a 42% discount, which is justified by its higher debt levels and the cyclicality of hospital admissions. Historically, Tenet's PE has ranged from 1.2x to 37.5x over the past five years, with the current 12.73x near the lower end of that range, indicating that the stock is trading at a discount to its own historical valuation, which could signal a value opportunity or reflect concerns about future growth.
PE
12.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 1x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant due to THC's high leverage, with a debt-to-equity ratio of 3.12 and quarterly interest expense of $205M. While the company generates strong free cash flow of $3.349B TTM, a prolonged downturn in patient volumes or a rise in interest rates could strain its ability to service debt. Additionally, revenue growth has decelerated to 2.78% YoY, and the company cited an unfavorable admissions mix, which could persist and pressure top-line growth. The net margin improvement to 13.08% is impressive, but it may be partly due to one-time items or cost cuts that are not sustainable long-term.
FAQ
The key risks of holding THC include: 1) High financial leverage, with a debt-to-equity ratio of 3.12, which increases vulnerability to interest rate hikes and economic downturns; 2) Revenue growth deceleration, as seen in Q1 2026 with only 2.78% YoY growth, which could persist if admissions mix issues continue; 3) Regulatory and competitive risks in the healthcare sector, including potential changes to Medicare/Medicaid reimbursement; 4) Market risk due to a beta of 1.23, meaning the stock is more volatile than the market. The most severe risk is a combination of these factors leading to a decline to the 52-week low of $157.58, a -43.9% drop from current levels.
The 12-month forecast for THC is moderately bullish. In the base case (50% probability), the stock is expected to trade around the analyst average target of $282.48, with a range of $270-$290. In the bull case (30% probability), the stock could reach the high target of $309, driven by continued margin expansion and revenue acceleration. In the bear case (20% probability), the stock could decline to $260 or lower if revenue growth stalls or regulatory headwinds emerge. The most likely scenario is the base case, where the stock remains near current levels, with modest upside potential. The key assumption is that the company maintains its net margin above 12% and revenue growth of at least 2%.
Based on valuation metrics, THC appears undervalued relative to its earnings power. The trailing PE of 12.73x is 42% below the industry average of 22x, and the forward PE of 13.47x suggests the market expects modest earnings growth. The price-to-sales ratio of 0.84x is also low, indicating the stock is trading at a discount to its revenue generation. However, the high debt-to-equity ratio of 3.12 and decelerating revenue growth may justify some discount. Historically, THC's PE has ranged from 1.2x to 37.5x, and the current level is near the lower end, suggesting the stock is undervalued relative to its own history. The market appears to be pricing in concerns about future growth, but if the company can sustain its margin expansion, the stock could re-rate higher.
THC is a good buy for investors seeking a value-oriented healthcare stock with strong earnings growth. The trailing PE of 12.73x is well below the industry average of 22x, and the company's net margin expanded to 13.08% in Q1 2026, indicating strong profitability. However, the average analyst target of $282.48 offers only 0.6% upside, so the stock is fairly valued in the near term. The main risk is the high debt-to-equity ratio of 3.12, which could amplify downside in a downturn. For long-term investors, the stock offers a compelling risk/reward if earnings growth continues, but for short-term traders, the limited upside may not be attractive.
THC is suitable for both long-term and short-term investment, but it is better suited for long-term investors with a horizon of at least 3-5 years. The company's strong earnings growth and low valuation provide a solid foundation for long-term capital appreciation, and its free cash flow generation supports debt reduction and potential share buybacks. However, the stock's high beta of 1.23 and recent volatility make it less suitable for short-term trading, as it can experience significant swings. For short-term traders, the stock's momentum and relative strength could offer opportunities, but the limited upside to analyst targets suggests caution. A minimum holding period of 2-3 years is recommended to ride out market volatility and benefit from the company's operational improvements.
